Methods of Treating High Risk Multiple Myeloma
AssigneeJanssen Biotech, Inc.
InventorsTahamtan Ahmadi, Christopher Chiu, Ming Qi, Amy Sasser, Jordan Schecter
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Claims25
A method of treating multiple myeloma in a subject that had received two prior therapies, comprising administering to the subject a combination regimen comprising a therapeutically effective amount of daratumumab, bortezomib, and dexamethasone,
- wherein the subject achieves a complete response (CR);
- wherein the subject is minimal residual disease (MRD) negative after at least 6 months of achieving the CR;
- wherein the subject exhibits progression-free survival (PFS) of at least 16 months following initiation of the combination regimen;
- and
- wherein the method increases PFS compared to administering dexamethasone and bortezomib without the daratumumab.
A method of treating relapsed or refractory multiple myeloma in a subject that had received two prior therapies, comprising administering to the subject a combination regimen comprising a therapeutically effective amount of daratumumab, lenalidomide, and dexamethasone,
- wherein the subject achieves a CR;
- wherein the subject is MRD negative after at least 6 months of achieving the CR;
- wherein the subject exhibits PFS of at least 21 months following initiation of the combination regimen;
- and
- wherein the method increases PFS compared to administering dexamethasone and lenalidomide without the daratumumab.
Dependencies are inferred from the claim text.